TORONTO, July 11, 2024 - Profound Medical Corp (NASDAQ: PROF; TSX: PRN), a leading commercial-stage medical device company specializing in customizable, incision-free therapies for the ablation of diseased tissue, announced a significant development today. The U.S. Centers for Medicare and Medicaid Services (CMS) has proposed rules that establish a Category 1 CPT code for the Transurethral Ultrasound Ablation (TULSA) procedure. This landmark decision is set to come into effect on January 1, 2025.
The introduction of the Category 1 CPT codes for the TULSA procedure is a major milestone in the field of prostate disease treatment. This coding system establishes a uniform classification for medical services, enabling healthcare providers to accurately document and bill the specific procedure. The designation of a Category 1 CPT code signifies that the TULSA procedure is widely accepted and utilized within the medical community.
Profound Medical Corp’s TULSA procedure utilizes transurethral ultrasound guidance to deliver precise and controlled ablation to the prostate gland. By offering a non-invasive alternative to surgery, TULSA provides patients with a highly effective and customizable treatment for prostate diseases, including localized prostate cancer and benign prostatic hyperplasia (BPH). The introduction of Category 1 CPT codes ensures that this groundbreaking procedure will be more accessible to patients across the United States.
In addition to this significant regulatory achievement, Profound Medical Corp has also seen a substantial increase in its stock value, which rose by 5.09%. This surge can be attributed to the company’s impressive financial performance, particularly its return on average invested assets (ROI). In the fourth quarter of 2023, Profound Medical Corp achieved a record high ROI of 76.09%, indicating the company’s strong growth and potential for future success.
The record high ROI is a testament to Profound Medical Corp’s dedication to innovation and its commitment to improving patient outcomes. The company’s non-invasive therapies have proven to be highly effective, providing patients with safer and more accessible treatment options. With the introduction of Category 1 CPT codes for the TULSA procedure, Profound Medical Corp is poised to further revolutionize the field of prostate disease treatment.
By receiving Category 1 CPT codes, the TULSA procedure will gain greater recognition and acceptance within the medical community, paving the way for increased adoption and reimbursement. This will not only benefit patients seeking cutting-edge treatment options but also healthcare providers looking to offer the latest advancements in prostate disease treatment.
The proposed rules by CMS mark a significant step forward in advancing the accessibility and effectiveness of prostate disease treatment in the United States. By establishing a standardized coding system, CMS enables greater transparency, efficiency, and accuracy in billing and documentation. This will ultimately result in improved patient care, enhanced research opportunities, and a more comprehensive understanding of the impact of the TULSA procedure on prostate disease treatment outcomes.
In conclusion, Profound Medical Corp’s receipt of Category 1 CPT codes for the TULSA procedure and its record-breaking ROI showcase the company’s dedication to transforming the field of prostate disease treatment. Through its innovative and customizable therapies, Profound Medical Corp offers patients a non-invasive alternative to surgery, providing effective treatment options for various prostate diseases. The Category 1 CPT codes will further enhance the accessibility and adoption of the TULSA procedure, benefiting both patients and healthcare providers. This groundbreaking achievement signifies a promising future for the treatment of prostate diseases and reinforces Profound Medical Corp’s commitment to improving patient outcomes.
Comments